Herborium Group Updates Shareholders on Potential Acquisition
FORT LEE, N.J., June 13, 2012 /PRNewswire/ -- Herborium Group, Inc. (HBRM) www.herborium.com has issued an update on the proposed acquisition Term Sheet received from China based "China Health Resource, Inc.", a company that manufactures herbal ingredients for Traditional Chinese Medicines (TCM) in China. The Proposal from China Health Resource, Inc. includes proposals to merge China Resource, Inc. into Herborium Group, with Herborium to be the surviving public entity.
"Review of such Proposals involves detailed understanding of all aspects of a transaction by our Board of Directors, Legal Counsel, accounting experts along with guidance from our Investment Banker. This process will continue for the coming weeks. Shareholders will be provided with further information as appropriate," stated Dr. Agnes P. Olszewski, Herborium's Chairwoman and CEO.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sales its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com.
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.
For more information on this Press Release please inquire: Kinsley Street Investors Group. 732-513-6921 or write to: email@example.com